Testicular Dose From Prostate CyberKnife: A Cautionary Note in Regard to King et al. (Int J Radiat Oncol Biol Phys 2008;73:636-637)

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 2, 2009, Pages 637-

  Fuller, Donald B ^a  

^a San Diego CyberKnife Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CANCER RADIOTHERAPY; CYBERKNIFE; DOSIMETRY; FOLLOW UP; LETTER; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; TESTIS; TESTIS FUNCTION; TESTIS INJURY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 58149345585     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.09.003     Document Type: Letter

References (4)

1. King C.R., Lo A., and Kapp D.S. Testicular dose from prostate Cyberknife: A cautionary note. Int J Radiat Oncol Biol Phys 73 (2008) 636-637
2. Grills I.S., Martinez A.A., Hollander M., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171 (2004) 1098-1104
3. Fuller D.B., Naitoh J., Lee C., et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70 (2008) 1588-1597
4. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905